TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE

被引：6
|
作者：
Popat, S. [1 ]
Yang, J. C. H. [2 ]
Lungershausen, J. [3 ]
Griebsch, I [3 ]
Marten, A. [4 ]
Wu, Y. L. [5 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Natl Taiwan Univ, Taipei 10764, Taiwan
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2166
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A615 / A615
页数：1
相关论文
共 50 条
  • [31] P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR M plus NSCLC Treated with TKIEfficacy and Safety of Gefitinib for Elderly Patients with EGFR Mutation Positive NSCLC
    Kusaka, Kei
    Hirose, Takashi
    Tamura, Atsuhisa
    Ide, Satoshi
    Saito, Minako
    Ogiya, Masahiro
    Inoue, Eri
    Tashimo, Hiroyuki
    Yamane, Akira
    Matsui, Hirotoshi
    Ohta, Ken
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S647 - S648
  • [32] Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Yvette N. Lamb
    Targeted Oncology, 2021, 16 : 869 - 869
  • [33] Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC
    Shamni, Ofer
    Grievink, Hilbert
    Itamar, Batel
    Mishani, Eyal
    Abourbeh, Galith
    MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (04) : 696 - 704
  • [34] Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations
    Yang, J. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S860 - S861
  • [35] Multicenter, Randomized, Double-Blind Study of Erlotinib plus Ramucirumab or Placebo in Patients with EGFR Mutation-Positive Metastatic NSCLC
    Garon, Edward B.
    Reck, Martin
    Vidal, Oscar J.
    Nadal, Ernest
    Lee, Pablo
    Dalal, Rita
    Liu, Jingyi
    He, Shuang
    Treat, Joseph
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S552 - S552
  • [36] Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis
    Feinberg, Bruce
    Halmos, Balazs
    Gucalp, Rasim
    Tang, Wenbo
    Moehring, Barbara
    Hochmair, Maximillian J.
    FUTURE ONCOLOGY, 2020, 16 (22) : 1585 - 1595
  • [37] Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies
    Meng, Ying
    Bai, Rilan
    Cui, Jiuwei
    THORACIC CANCER, 2023, 14 (13) : 1121 - 1134
  • [38] Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
    Mok, T.
    Nakagawa, K.
    Rosell, R.
    Lee, K.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Devgan, G.
    Sbar, E.
    Quinn, S.
    Wang, T.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S454 - S454
  • [39] The relationship between EGFR variant allele frequency and efficacy of osimertinib in EGFR mutation-positive NSCLC
    Katakura, Seigo
    Murakami, Shuji
    Kanako, Shinada
    Ryota, Ushio
    Tetsuro, Kondo
    Terufumi, Kato
    Tomoyuki, Yokose
    Haruhiro, Saito
    ANNALS OF ONCOLOGY, 2022, 33 : S500 - S500
  • [40] COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M plus ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Sequist, Lecia V.
    Yang, James C.
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Schuler, Martin
    Mok, Tony
    Geater, Sarayut Lucien
    Massey, Daniel
    Wind, Sven
    O'Brien, Dennis
    Lorence, Robert
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1197 - S1197
12345